Jump to ContentJump to Main Navigation
Show Summary Details

Clinical Chemistry and Laboratory Medicine (CCLM)

Published in Association with the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)

Editor-in-Chief: Plebani, Mario

Ed. by Gillery, Philippe / Lackner, Karl J. / Lippi, Giuseppe / Melichar, Bohuslav / Payne, Deborah A. / Schlattmann, Peter / Tate, Jillian R.

IMPACT FACTOR increased in 2015: 3.017
Rank 5 out of 30 in category Medical Laboratory Technology in the 2014 Thomson Reuters Journal Citation Report/Science Edition

SCImago Journal Rank (SJR) 2015: 0.873
Source Normalized Impact per Paper (SNIP) 2015: 0.982
Impact per Publication (IPP) 2015: 2.238

249,00 € / $374.00 / £187.00*

See all formats and pricing


Select Volume and Issue


Hypoadiponectinemia is associated with symptomatic atherosclerotic peripheral arterial disease

Benjamin Dieplinger1 / Werner Poelz2 / Meinhard Haltmayer3 / Thomas Mueller4





Corresponding author: Thomas Mueller, Department of Laboratory Medicine, Konventhospital Barmherzige Brueder, Seilerstaette 2-4, 4020 Linz, Austria Phone: +43-732-76773621, Fax: +43-732-76773799,

Citation Information: Clinical Chemical Laboratory Medicine. Volume 44, Issue 7, Pages 830–833, ISSN (Online) 1437-4331, ISSN (Print) 1434-6621, DOI: 10.1515/CCLM.2006.145, June 2006

Publication History

January 30, 2006
March 10, 2006
Published Online:


There is growing evidence that adiponectin, an adipocytokine with anti-inflammatory and antiathero-genic properties, is involved in the development of atherosclerosis. The aim of the present study was to examine whether serum levels of adiponectin were associated with symptomatic atherosclerotic peripheral arterial disease (PAD). Serum concentrations of adiponectin were measured in 433 patients with symptomatic PAD and 433 controls from the Linz Peripheral Arterial Disease (LIPAD) study. Cases and controls were matched for age, sex and diabetes mellitus. The median serum level of adiponectin was significantly lower in PAD patients than in control subjects (9.5 vs. 10.8 mg/L; p=0.014). After adjustment for several possible confounding variables using multivariable logistic regression, odds ratios for symptomatic PAD were 0.95 (95% CI, 0.64–1.42; p=0.080) and 0.59 (95% CI, 0.36–0.97; p=0.037) in the second and third tertiles for adiponectin serum concentrations, respectively, compared with the first tertile. Low serum levels of adiponectin were associated with the presence of symptomatic atherosclerotic PAD, independent of traditional and non-traditional risk factors, suggesting that hypoadiponectinemia may be a marker for systemic atherosclerotic disease.

Clin Chem Lab Med 2006;44:830–3.

Keywords: adiponectin; atherosclerosis; peripheral vascular disease; risk factors

Citing Articles

Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.

Thomas Mueller, Franz Hinterreiter, Christian Luft, Werner Poelz, Meinhard Haltmayer, and Benjamin Dieplinger
Journal of Vascular Surgery, 2014, Volume 59, Number 5, Page 1291
Claudia D. Gherman, Doru Pamfil, and Sorana D. Bolboacă
BioMed Research International, 2013, Volume 2013, Page 1
Claudia D. Gherman and Aurel I. Mironiuc
Mediators of Inflammation, 2012, Volume 2012, Page 1
Benjamin Dieplinger, Werner Poelz, Meinhard Haltmayer, and Thomas Mueller
Clinica Chimica Acta, 2007, Volume 377, Number 1-2, Page 192
Grazina Urbonaviciene, Jan Frystyk, Allan Flyvbjerg, Eskild W. Henneberg, and Jes S. Lindholt
Atherosclerosis, 2010, Volume 210, Number 2, Page 619
José Luis Zamorano and Alexandra Gonçalves
Cardiology, 2011, Volume 118, Number 4, Page 248
C. Antoniades, A. S. Antonopoulos, D. Tousoulis, and C. Stefanadis
Obesity Reviews, 2009, Volume 10, Number 3, Page 269
Nephrology, 2007, Volume 12, Number 6, Page 546

Comments (0)

Please log in or register to comment.